Clinical Trial Update: A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy [Phase 2]

View source ↗

Summary

This Phase II trial evaluated Axitinib in patients with clear-cell metastatic renal cell carcinoma unsuitable for nephrectomy and has completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)

Snippet

Sponsor: Institute of Cancer Research, United Kingdom | Conditions: Clear-cell Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-11-21